( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Rachel Norris, MD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback